PMID- 19344291
OWN - NLM
STAT- MEDLINE
DCOM- 20091223
LR  - 20211020
IS  - 1937-335X (Electronic)
IS  - 1937-3341 (Print)
IS  - 1937-3341 (Linking)
VI  - 15
IP  - 10
DP  - 2009 Oct
TI  - Chondroitinase ABC treatment results in greater tensile properties of 
      self-assembled tissue-engineered articular cartilage.
PG  - 3119-28
LID - 10.1089/ten.TEA.2008.0478 [doi]
AB  - Collagen content and tensile properties of engineered articular cartilage have 
      remained inferior to glycosaminoglycan (GAG) content and compressive properties. 
      Based on a cartilage explant study showing greater tensile properties after 
      chondroitinase ABC (C-ABC) treatment, C-ABC as a strategy for cartilage tissue 
      engineering was investigated. A scaffold-less approach was employed, wherein 
      chondrocytes were seeded into non-adherent agarose molds. C-ABC was used to 
      deplete GAG from constructs 2 weeks after initiating culture, followed by 2 weeks 
      culture post-treatment. Staining for GAG and type I, II, and VI collagen and 
      transmission electron microscopy were performed. Additionally, quantitative total 
      collagen, type I and II collagen, and sulfated GAG content were measured, and 
      compressive and tensile mechanical properties were evaluated. At 4 wks, C-ABC 
      treated construct ultimate tensile strength and tensile modulus increased 121% 
      and 80% compared to untreated controls, reaching 0.5 and 1.3 MPa, respectively. 
      These increases were accompanied by increased type II collagen concentration, 
      without type I collagen. As GAG returned, compressive stiffness of C-ABC treated 
      constructs recovered to be greater than 2 wk controls. C-ABC represents a novel 
      method for engineering functional articular cartilage by departing from 
      conventional anabolic approaches. These results may be applicable to other 
      GAG-producing tissues functioning in a tensile capacity, such as the 
      musculoskeletal fibrocartilages.
FAU - Natoli, Roman M
AU  - Natoli RM
AD  - Department of Bioengineering, Rice University, Houston, Texas 77005, USA.
FAU - Revell, Christopher M
AU  - Revell CM
FAU - Athanasiou, Kyriacos A
AU  - Athanasiou KA
LA  - eng
GR  - R01AR053286/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
RN  - 0 (Glycosaminoglycans)
RN  - EC 4.2.2.20 (Chondroitin ABC Lyase)
SB  - IM
MH  - Biomechanical Phenomena
MH  - Cartilage, Articular/*cytology/*drug effects/metabolism/ultrastructure
MH  - Chondroitin ABC Lyase/*metabolism/*pharmacology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Glycosaminoglycans/metabolism
MH  - Microscopy, Electron, Transmission
MH  - Tensile Strength/*drug effects
MH  - Tissue Engineering/*methods
PMC - PMC2792048
EDAT- 2009/04/07 09:00
MHDA- 2009/12/24 06:00
PMCR- 2010/10/01
CRDT- 2009/04/07 09:00
PHST- 2009/04/07 09:00 [entrez]
PHST- 2009/04/07 09:00 [pubmed]
PHST- 2009/12/24 06:00 [medline]
PHST- 2010/10/01 00:00 [pmc-release]
AID - 10.1089/ten.tea.2008.0478 [pii]
AID - 10.1089/ten.TEA.2008.0478 [doi]
PST - ppublish
SO  - Tissue Eng Part A. 2009 Oct;15(10):3119-28. doi: 10.1089/ten.TEA.2008.0478.